Brokerages Set Prestige Consumer Healthcare Inc. (NYSE:PBH) Target Price at $70.75

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) have earned an average rating of “Hold” from the six research firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $70.75.

PBH has been the subject of a number of research reports. Jefferies Financial Group reduced their price objective on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a research note on Friday, January 30th. Canaccord Genuity Group lowered their target price on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a research report on Friday, May 15th. Zacks Research cut shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a report on Monday, May 18th. Oppenheimer downgraded shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. Finally, Weiss Ratings cut shares of Prestige Consumer Healthcare from a “hold (c)” rating to a “hold (c-)” rating in a research note on Thursday, May 14th.

Insider Activity at Prestige Consumer Healthcare

In other news, VP Jeffrey Zerillo sold 1,207 shares of the company’s stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total value of $66,372.93. Following the completion of the sale, the vice president directly owned 42,820 shares of the company’s stock, valued at approximately $2,354,671.80. This represents a 2.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.40% of the company’s stock.

Institutional Trading of Prestige Consumer Healthcare

Several institutional investors and hedge funds have recently added to or reduced their stakes in PBH. UMB Bank n.a. lifted its position in Prestige Consumer Healthcare by 110.1% during the 4th quarter. UMB Bank n.a. now owns 418 shares of the company’s stock worth $26,000 after acquiring an additional 219 shares during the period. Bayforest Capital Ltd acquired a new position in shares of Prestige Consumer Healthcare in the fourth quarter valued at approximately $29,000. First Horizon Corp acquired a new position in shares of Prestige Consumer Healthcare in the third quarter valued at approximately $32,000. Barrow Hanley Mewhinney & Strauss LLC raised its stake in shares of Prestige Consumer Healthcare by 106.8% during the third quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 548 shares of the company’s stock worth $34,000 after purchasing an additional 283 shares during the last quarter. Finally, Geneos Wealth Management Inc. raised its stake in shares of Prestige Consumer Healthcare by 92.8% during the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock worth $48,000 after purchasing an additional 269 shares during the last quarter. 99.95% of the stock is owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Stock Performance

Shares of PBH stock opened at $48.02 on Monday. The stock’s 50-day moving average is $55.97 and its two-hundred day moving average is $60.90. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.25 and a current ratio of 3.57. Prestige Consumer Healthcare has a 1 year low of $42.62 and a 1 year high of $87.12. The firm has a market cap of $2.27 billion, a price-to-earnings ratio of 12.28, a PEG ratio of 1.55 and a beta of 0.40.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Wednesday, May 13th. The company reported $1.23 earnings per share for the quarter, missing the consensus estimate of $1.39 by ($0.16). The firm had revenue of $281.62 million during the quarter, compared to analysts’ expectations of $293.64 million. Prestige Consumer Healthcare had a net margin of 17.48% and a return on equity of 11.54%. The firm’s revenue for the quarter was down 5.0% on a year-over-year basis. During the same period in the previous year, the firm posted $1.32 earnings per share. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. Analysts predict that Prestige Consumer Healthcare will post 4.45 earnings per share for the current year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).